Spravato® (Esketamine) Therapy for Treatment-Resistent Depression
When standard antidepressants haven’t provided the relief you need, Spravato® offers a new pathway to hope. As the first FDA-approved nasal spray specifically designed for treatment-resistant depression (TRD), Spravato® works differently than traditional medications to help you reclaim your life.
A Breakthrough in Depression Care
Spravato® (esketamine) is a CIII controlled substance that is administered as a nasal spray. It is specifically indicated for use alongside a traditional oral antidepressant for adults who have struggled to find relief from multiple treatments.
- A Unique Mechanism: Unlike most antidepressants that target serotonin or norepinephrine, Spravato® is an NMDA receptor antagonist. It works on a different pathway in the brain to help restore vital neural connections.
- Proven Results: The efficacy of Spravato® has been demonstrated in clinical studies involving over 1,700 adult patients living with treatment-resistant depression.
- Targeted Support: It is designed to be used in conjunction with an oral antidepressant, providing a dual-layered approach to managing your mental health.
Take the Next Step Toward Healing
We are committed to helping you find a treatment plan that works. Please fill out the short form below, and someone from our care team will be in touch. Thank you!
Frequently Asked Questions
Treatment-resistant depression is typically defined as a situation where an adult has tried at least two different antidepressant treatments at adequate doses and durations during a depressive episode but has not experienced significant improvement.
Most oral antidepressants work by increasing levels of certain chemicals in the brain. Spravato® works by targeting the NMDA receptors, which helps the brain create new connections and pathways, often leading to relief for those who didn’t respond to older classes of medication.
Spravato® is a nasal spray that you administer yourself under the direct supervision of a healthcare provider at our certified treatment center. Because of the nature of the medication, you will remain at the clinic for at least two hours of observation after each dose to ensure your safety and comfort.
During your visit, you will be in a comfortable, monitored environment. Because Spravato® can cause temporary sedation or changes in perception, you will need to arrange for a ride home from the clinic. You should not drive or operate heavy machinery until the day after your treatment session.
Spravato® is FDA-approved and has been extensively studied. Our clinical team will monitor you closely during and after each session to manage any potential side effects.
If you are an adult struggling with severe depression and have not seen results from at least two different oral antidepressants, you may be a candidate for Spravato®.